Adding stereotactic ablative radiotherapy (SAbR) to neoadjuvant chemotherapy improves pathologic outcomes for patients ...

Alfa Cytology has announced tumor models customization service for pancreatic cancer research. HAUPPAUGE, NEW YORK, USA, July 18, 2024 /EINP Tuesday, 02 January 2024 12:17 GMT ...

Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer. Learn about symptoms, causes, diagnosis, treatment, and outlook.

For the pancreatic adenocarcinoma group, the median age was 49 years and 43% were female. Nearly all (87%) patients were White, followed by 7% Asian and 3.3% Black. These patients also received a ...

Announcing a new publication for Acta Materia Medica journal. Chemoresistance to gemcitabine (Gem) remains a substantial obstacle in the treatment of pancreatic ductal adenocarcinoma carcinoma (PDAC).

Pancreatic adenocarcinoma incidence is rising across all age groups, with the highest APC of 4.35 in the 15 to 34 age group. The SEER database, covering 47.9% of the US population, ...

Bizengri received FDA approval for NSCLC and pancreatic adenocarcinoma with NRG1 gene fusion after prior therapy failure. The eNRGy study showed a 33% ORR in NSCLC and 40% in pancreatic adenocarcinoma ...

Pancreatic adenocarcinoma incidence increased among all age groups. Most cases occurred among patients aged 55 years and older (n = 239,840), followed by those aged 35 to 54 years (n = 33,800) and ...

Risk Increases. A dose-response relationship was evident. For an increase in pesticide use of 2.5 kg/hectare over 11 years, the risk for pancreatic adenocarcinoma increased from 0.9% to 1.4%.